244 related articles for article (PubMed ID: 9666478)
1. Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: correlation between the density of inclusions and IT15 CAG triplet repeat length.
Becher MW; Kotzuk JA; Sharp AH; Davies SW; Bates GP; Price DL; Ross CA
Neurobiol Dis; 1998 Apr; 4(6):387-97. PubMed ID: 9666478
[TBL] [Abstract][Full Text] [Related]
2. Uninterrupted CAG repeat drives striatum-selective transcriptionopathy and nuclear pathogenesis in human Huntingtin BAC mice.
Gu X; Richman J; Langfelder P; Wang N; Zhang S; Bañez-Coronel M; Wang HB; Yang L; Ramanathan L; Deng L; Park CS; Choi CR; Cantle JP; Gao F; Gray M; Coppola G; Bates GP; Ranum LPW; Horvath S; Colwell CS; Yang XW
Neuron; 2022 Apr; 110(7):1173-1192.e7. PubMed ID: 35114102
[TBL] [Abstract][Full Text] [Related]
3. Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington's disease mice.
Li H; Li SH; Yu ZX; Shelbourne P; Li XJ
J Neurosci; 2001 Nov; 21(21):8473-81. PubMed ID: 11606636
[TBL] [Abstract][Full Text] [Related]
4. From neuronal inclusions to neurodegeneration: neuropathological investigation of a transgenic mouse model of Huntington's disease.
Davies SW; Turmaine M; Cozens BA; Raza AS; Mahal A; Mangiarini L; Bates GP
Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):971-9. PubMed ID: 10434295
[TBL] [Abstract][Full Text] [Related]
5. Genetics and neuropathology of Huntington's disease.
Reiner A; Dragatsis I; Dietrich P
Int Rev Neurobiol; 2011; 98():325-72. PubMed ID: 21907094
[TBL] [Abstract][Full Text] [Related]
6. Faulty splicing and cytoskeleton abnormalities in Huntington's disease.
Fernández-Nogales M; Santos-Galindo M; Hernández IH; Cabrera JR; Lucas JJ
Brain Pathol; 2016 Nov; 26(6):772-778. PubMed ID: 27529534
[TBL] [Abstract][Full Text] [Related]
7. Cdc42-interacting protein 4 binds to huntingtin: neuropathologic and biological evidence for a role in Huntington's disease.
Holbert S; Dedeoglu A; Humbert S; Saudou F; Ferrante RJ; Néri C
Proc Natl Acad Sci U S A; 2003 Mar; 100(5):2712-7. PubMed ID: 12604778
[TBL] [Abstract][Full Text] [Related]
8. Toward understanding the molecular pathology of Huntington's disease.
Wellington CL; Brinkman RR; O'Kusky JR; Hayden MR
Brain Pathol; 1997 Jul; 7(3):979-1002. PubMed ID: 9217979
[TBL] [Abstract][Full Text] [Related]
9. Influence of species differences on the neuropathology of transgenic Huntington's disease animal models.
Li XJ; Li S
J Genet Genomics; 2012 Jun; 39(6):239-45. PubMed ID: 22749010
[TBL] [Abstract][Full Text] [Related]
10. Degeneration of the cerebellum in Huntington's disease (HD): possible relevance for the clinical picture and potential gateway to pathological mechanisms of the disease process.
Rüb U; Hoche F; Brunt ER; Heinsen H; Seidel K; Del Turco D; Paulson HL; Bohl J; von Gall C; Vonsattel JP; Korf HW; den Dunnen WF
Brain Pathol; 2013 Mar; 23(2):165-77. PubMed ID: 22925167
[TBL] [Abstract][Full Text] [Related]
11. DNA instability in postmitotic neurons.
Gonitel R; Moffitt H; Sathasivam K; Woodman B; Detloff PJ; Faull RL; Bates GP
Proc Natl Acad Sci U S A; 2008 Mar; 105(9):3467-72. PubMed ID: 18299573
[TBL] [Abstract][Full Text] [Related]
12. Childhood-onset (Juvenile) Huntington's disease: A rare case report.
Patra KC; Shirolkar MS
J Pediatr Neurosci; 2015; 10(3):276-9. PubMed ID: 26557176
[TBL] [Abstract][Full Text] [Related]
13. Elucidating the Impact of Deleterious Mutations on IGHG1 and Their Association with Huntington's Disease.
Shafie A; Ashour AA; Anjum F; Shamsi A; Hassan MI
J Pers Med; 2024 Apr; 14(4):. PubMed ID: 38673007
[TBL] [Abstract][Full Text] [Related]
14. Intracerebral Distribution of CAG Repeat-Binding Small Molecule Visualized by Whole-Brain Imaging.
Murakami E; Nakamori M; Nakatani K; Shibata T; Tainaka K
Bioconjug Chem; 2023 Dec; 34(12):2187-2193. PubMed ID: 37948852
[TBL] [Abstract][Full Text] [Related]
15. Correction: Huntingtin HTT1a is generated in a CAG repeat-length-dependent manner in human tissues.
Hoschek F; Natan J; Wagner M; Sathasivam K; Abdelmoez A; Einem BV; Bates GP; Landwehrmeyer GB; Neueder A
Mol Med; 2024 Apr; 30(1):49. PubMed ID: 38600455
[No Abstract] [Full Text] [Related]
16. The Emerging Landscape of Natural Small-molecule Therapeutics for Huntington's Disease.
Bhat SA; Ahamad S; Dar NJ; Siddique YH; Nazir A
Curr Neuropharmacol; 2023; 21(4):867-889. PubMed ID: 36797612
[TBL] [Abstract][Full Text] [Related]
17. Emerging Role of NLRP3 Inflammasome/Pyroptosis in Huntington's Disease.
Paldino E; Fusco FR
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35955494
[TBL] [Abstract][Full Text] [Related]
18. Small-Molecule Disruptors of Mutant Huntingtin-Calmodulin Protein-Protein Interaction Attenuate Deleterious Effects of Mutant Huntingtin.
Kapadia K; Trojniak AE; Guzmán Rodríguez KB; Klus NJ; Huntley C; McDonald P; Roy A; Frankowski KJ; Aubé J; Muma NA
ACS Chem Neurosci; 2022 Aug; 13(15):2315-2337. PubMed ID: 35833925
[TBL] [Abstract][Full Text] [Related]
19. The distribution and density of Huntingtin inclusions across the Huntington disease neocortex: regional correlations with Huntingtin repeat expansion independent of pathologic grade.
Hickman RA; Faust PL; Marder K; Yamamoto A; Vonsattel JP
Acta Neuropathol Commun; 2022 Apr; 10(1):55. PubMed ID: 35440014
[TBL] [Abstract][Full Text] [Related]
20. Impact of ER Stress and ER-Mitochondrial Crosstalk in Huntington's Disease.
Maity S; Komal P; Kumar V; Saxena A; Tungekar A; Chandrasekar V
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
